Evidence map›Paper›PMID 37900631›Full record

ArticleIndian journal of surgical oncology2023

Lymph Node Metastasis and Patterns of Recurrence in Vulvar Carcinoma: 10 Years' Single Center Experience.

Yamini Kansal, Rajshekar S Kundargi, Pallavi V R, Shobha Krishnappa, Esha Shanbhag, Punyashree, Neha Jain, Vijay C R, U D Bafna

Open access · greenAbstract read
In one paragraph

Article in Indian journal of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yamini KansalDepartment of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India.
Rajshekar S KundargiDepartment of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India.
Pallavi V RDepartment of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India.
Shobha KrishnappaDepartment of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India.
Esha ShanbhagDepartment of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India.
PunyashreeDepartment of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India.
Neha JainDepartment of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India.
Vijay C RDepartment of Biostatistics, Kidwai Memorial Institute of Oncology, Bengaluru, India.
U D BafnaDepartment of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India.
Kidwai Memorial Institute of Oncology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vulvar carcinoma is a relatively rare malignancy and there is a paucity of data, especially from India and other developing countries regarding the prognostic factors impacting recurrence and survival. A retrospective observational study was conducted in the Department of Gynecologic Oncology at a tertiary care, regional cancer institute, including all patients with carcinoma vulva who underwent surgery between 2009 and 2018. Demographic profile, surgical-pathological information, details of neo-adjuvant chemotherapy, adjuvant radiation and chemotherapy, and peri-operative complications were analyzed. Long-term follow-up data was gathered, with an evaluation of various prognostic factors impacting recurrence and overall survival outcome. Forty-five cases with mean age of 56.2 years (range 29-82) were treated during the study period. Surgery was the initial treatment modality in 41 (91.1%) cases. Neo-adjuvant chemotherapy prior to surgery was given to four cases. After complete surgico-pathological staging, most patients had stage I disease (26 cases, 57.8%) and 22.2% had stage II disease. Owing to microscopic lymph node involvement, seven cases (15.6%) belonged to FIGO stage III disease. Two cases had stage IVA disease with fixed groin nodes. Adjuvant chemotherapy in the form of 5-fluoro uracil and cisplatin was administered to four out of the nine patients with nodal involvement. The remaining five were advised adjuvant groin radiation. At a median follow-up of 34 months (range 2-114 months), 12 cases (26.7%) experienced a recurrence and one case with stage IVA disease progressed during adjuvant chemotherapy. The 5-year overall survival was 76.6% and the 5-year disease-free survival was 69.6%. There were a total number of 10 deaths, of which seven were due to disease recurrence or progression and the remaining 30% of deaths were due to medical co-morbid conditions. Overall survival was negatively impacted by increasing age (age > 60 years), number of positive nodes, presence of perinodal spread, and stage of the disease. Recurrence-free survival was significantly reduced in those with the presence of peri-nodal spread and lympho-vascular space invasion. The incidence of lymph node metastasis was found to be higher in patients with age > 60 years, increasing tumor size, presence of lympho-vascular space invasion and the number of lymph nodes removed. In carcinoma vulva, treatment should be individualized with multidisciplinary cooperation. In our series, we found that the stage of disease, nodal positivity, and nodal positivity with extra-capsular spread were significant prognostic factors impacting survival on analysis. Lymph nodal positivity was associated with increasing tumour size, presence of lympho-vascular invasion, and patient age.

Indexed as

Lymph node metastasisNeo-adjuvant chemotherapyPrognostic factorsRadiation therapyRecurrence patternVulvar carcinoma

Identifiers

PMID37900631
PMCPMC10611681
OpenAlexW4322485784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.